You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

checkpoint inhibitor naive

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Advanced Solid Tumor Trial (INCB099280)

Not yet recruiting
  • Advanced Solid Tumor
  • (no location specified)
May 19, 2023

Urothelial Cancer Trial run by the NCI (Bintrafusp alfa (M7824))

Terminated
Has Results
  • Urothelial Cancer
  • Bintrafusp alfa (M7824)
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Feb 25, 2022

Melanoma, Uveal Trial in Portland (Pembrolizumab, Lenvatinib)

Recruiting
  • Melanoma, Uveal
  • Portland, Oregon
    Providence Portland Medical Center
Aug 2, 2022

Ovarian Cancer Trial in United States (Magrolimab, Avelumab)

Completed
  • Ovarian Cancer
  • Chicago, Illinois
  • +5 more
Jul 26, 2021

Non Small Cell Lung Cancer, Urothelial Cancer, Renal Cell Carcinoma Trial in Worldwide (INCB086550)

Active, not recruiting
  • Non Small Cell Lung Cancer
  • +4 more
  • Burgas, Bulgaria
  • +19 more
Oct 20, 2022

Pancreatic Cancer, Adenocarcinoma of the Pancreas, Adenocarcinoma Trial in New York, Providence (Motixafortide, Cemiplimab,

Recruiting
  • Pancreatic Cancer
  • +2 more
  • New York, New York
  • +1 more
Nov 7, 2022

Melanoma Stage III, Melanoma Stage IV Trial in Wollstonecraft, Nedlands (EVX-01, Pembrolizumab 25 MG/ML)

Not yet recruiting
  • Melanoma Stage III
  • Melanoma Stage IV
  • Wollstonecraft, New South Wales, Australia
  • +2 more
May 11, 2022

Malignant Ascites Trial in Taichung (Nivolumab, Pembrolizumab)

Enrolling by invitation
  • Malignant Ascites
  • Taichung, Please Select, Taiwan
    China Medical University Hospital
Feb 16, 2023

Immune Checkpoint Inhibitor-related Cardiotoxicity

Not yet recruiting
  • Immune Checkpoint Inhibitors, Cardiotoxicity
  • Cardiac magnetic resonance
  • (no location specified)
Nov 10, 2023

Severe Checkpoint Inhibitor Pneumonitis Trial in Beijing (Corticosteroids, Corticosteroids and Ruxolitinib)

Recruiting
  • Severe Checkpoint Inhibitor Pneumonitis
  • Beijing, Beijing, China
    Department of Respiratory Medicine, Peking Union Medical College
Jun 12, 2023

Gastrointestinal Tumor Trial in Hangzhou (Water-filtered infrared A radiation whole-body hyperthermia (HECKEL 3000MT-4T,

Completed
  • Gastrointestinal Tumor
  • Water-filtered infrared A radiation whole-body hyperthermia (HECKEL 3000MT-4T, Germany)
  • tislelizumab (BeiGene, China) combined with PD-1 inhibitor
  • Hangzhou, China
    Zhejiang Hospital
Sep 1, 2023

Metastatic Pancreatic Cancer Trial in Rotterdam (Durvalumab, Rintatolimod)

Not yet recruiting
  • Metastatic Pancreatic Cancer
  • Durvalumab
  • Rintatolimod
  • Rotterdam, Zuid-Holland, Netherlands
    Erasmus MC
Jun 23, 2023

Inflammatory Arthritis, Immune-related Adverse Event Trial (Adalimumab, Prednisone)

Not yet recruiting
  • Inflammatory Arthritis
  • Immune-related Adverse Event
  • (no location specified)
Sep 13, 2023

Determine Pro-Inflammatory Cytokine Kinetics During Immune

Not yet recruiting
  • Non Small Cell Lung Cancer
  • Melanoma
    • Indianapolis, Indiana
      Indiana University Melvin and Bren Simon Comprehensive Cancer Ce
    Jan 30, 2023

    NSCLC Associated With Leptomeningeal Metastases Trial (Tislelizumab, pemetrexed)

    Not yet recruiting
    • NSCLC Associated With Leptomeningeal Metastases
    • Tislelizumab, pemetrexed
    • (no location specified)
    Nov 21, 2023

    Immune Checkpoint Inhibitor Monotherapy or Combined With

    Not yet recruiting
    • Immune Checkpoint Inhibitor Monotherapy or Combined With Molecular Targeting Drugs / Locoregional Therapy for Hepatocellular Carcinoma
    • Immune checkpoint inhibitor
    • Guangzhou, Guangdong, China
      Department of Minimally Invasive and Interventional Radiology, L
    Jan 30, 2023

    Advanced or Metastatic Solid Tumors, Microsatellite Instability Low, Microsatellite Instability High Trial in United States

    Recruiting
    • Advanced or Metastatic Solid Tumors
    • +11 more
    • Tucson, Arizona
    • +11 more
    Dec 2, 2022

    Lung Squamous Cell Carcinoma Trial in Yancheng (To explore the efficacy and safety of immune checkpoint inhibitor combined with

    Recruiting
    • Lung Squamous Cell Carcinoma
    • To explore the efficacy and safety of immune checkpoint inhibitor combined with endostar and chemotherapy in the treatment of advanced lung squamous cell carcinoma (stage IIIB-IV).
    • Yancheng, Jiangsu, China
      Yancheng Clinical College of Xuzhou Medical University
    Mar 21, 2023

    Nasopharyngeal Carcinoma, Immune Checkpoint Inhibitor, Radiotherapy Trial (radiation, drug, biological)

    Not yet recruiting
    • Nasopharyngeal Carcinoma
    • +3 more
    • Intensity Modulated Radiation Therapy
    • +3 more
    • (no location specified)
    Jul 11, 2023

    Primary and Metastatic Tumors in Renal Cell Carcinoma and

    Recruiting
    • Renal Cell Carcinoma
    • +4 more
    • Immune checkpoint inhibitor targeting PD1
    • Philadelphia, Pennsylvania
      Fox Chase Cancer Center - Philadelphia
    Jan 27, 2023

    Advanced Biliary Tract Cancer Trial in Shanghai (Sintilimab, Lenvatinib, Cryoablation)

    Recruiting
    • Advanced Biliary Tract Cancer
    • Shanghai, Shanghai, China
      Fudan University Shanghai Cancer Center
    Mar 22, 2023

    Stage IV NSCLC Trial in Houston (Poly ICLC, IVIG)

    Not yet recruiting
    • Stage IV NSCLC
    • Houston, Texas
      Michael E. DeBakey VA Medical Center, Houston, TX
    Sep 28, 2023

    Advanced Solid Tumor, Metastatic Solid Tumor Trial (PEP07)

    Not yet recruiting
    • Advanced Solid Tumor
    • Metastatic Solid Tumor
    • (no location specified)
    Aug 1, 2023

    Melanoma Trial in Toulouse (Nivolumab+Ipilimumab in combination with Anti TNF-a Certolizumab, Nivolumab+Ipilimumab in

    Active, not recruiting
    • Melanoma
    • Nivolumab+Ipilimumab in combination with Anti TNF-α Certolizumab
    • Nivolumab+Ipilimumab in combination with Anti TNF-α Infliximab
    • Toulouse, France
      Institut Claudius Regaud IUCT-ONCOPOLE
    Nov 18, 2022

    EXploring Immune-related Adverse Events of Immune checkpoinT

    Active, not recruiting
    • Cancer
    • +2 more
    • Immune checkpoint inhibitor
    • Paris, France
    • +1 more
    Jul 5, 2023